NuVasive (NASDAQ:NUVA) will be issuing its quarterly earnings data after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $0.56 per share for the quarter.
NuVasive (NUVA) opened at $47.86 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.51 and a current ratio of 2.85. NuVasive has a 12 month low of $44.62 and a 12 month high of $81.68. The firm has a market cap of $2,490.00, a P/E ratio of 40.22, a PEG ratio of 1.32 and a beta of 0.50.
A number of research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Leerink Swann cut shares of NuVasive from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 1st. Wells Fargo & Co cut shares of NuVasive from an “outperform” rating to a “market perform” rating and set a $65.00 price objective for the company. in a research note on Wednesday, January 17th. BidaskClub cut shares of NuVasive from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $90.00 price objective on shares of NuVasive in a research note on Tuesday, January 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $71.19.
WARNING: “NuVasive (NUVA) to Release Quarterly Earnings on Monday” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/25/nuvasive-nuva-to-release-quarterly-earnings-on-monday.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.